- Trials with a EudraCT protocol (43,691)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
43,691 result(s) found.
Displaying page 1,786 of 2,185.
EudraCT Number: 2011-002667-14 | Sponsor Protocol Number: UHKT-RLP/2011 | Start Date*: 2011-07-19 | |||||||||||
Sponsor Name:Institute of Hematology and Blood Transfusion | |||||||||||||
Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients? | |||||||||||||
Medical condition: Recurrent respiratory papillomatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002560-10 | Sponsor Protocol Number: NOA-07 | Start Date*: 2008-11-04 | |||||||||||
Sponsor Name:Freistaat Bayern, represented by the University of Regensburg | |||||||||||||
Full Title: Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07) | |||||||||||||
Medical condition: Therapy of medulloblastoma of adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000901-19 | Sponsor Protocol Number: PSA‐PI‐006421 | Start Date*: 2017-09-11 |
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | ||
Full Title: Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis. | ||
Medical condition: Psoriasic arthritis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2019-002114-38 | Sponsor Protocol Number: KSL0118 | Start Date*: 2019-09-04 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Randomized, single dose, placebo-controlled, double-blind, parallel group study to evaluate the onset of pain response after administration of ketoprofen lysine salt 40 mg, in male and female subje... | |||||||||||||
Medical condition: pain management in odontoiatry | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002248-98 | Sponsor Protocol Number: TN-10 | Start Date*: 2016-01-15 | |||||||||||
Sponsor Name:TrialNet Coordinating Center | |||||||||||||
Full Title: Anti-CD3 mAb (teplizumab) for prevention of diabetes in relatives at-risk for Type 1 diabetes mellitus | |||||||||||||
Medical condition: Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004914-79 | Sponsor Protocol Number: CA017-003 | Start Date*: 2016-10-22 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors | |||||||||||||
Medical condition: Advanced Malignant Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Completed) FI (Completed) SE (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001677-28 | Sponsor Protocol Number: 2007/08 | Start Date*: 2007-11-28 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Quantification of the anesthetic effect of nitrous oxide using intravenous "closed-loop" anesthesia | ||
Medical condition: This is a study of the anesthetic effect of the IMP, nitrous oxide. In this sense "general anesthesia" can be termed the medical condition under investigation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003662-27 | Sponsor Protocol Number: CA209-9X8 | Start Date*: 2018-04-04 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014444-11 | Sponsor Protocol Number: RET04.09 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS | |||||||||||||
Full Title: Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib | |||||||||||||
Medical condition: Diabetic Macular Edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005002-30 | Sponsor Protocol Number: ICORG09-13 | Start Date*: 2012-01-05 | |||||||||||
Sponsor Name:ICORG-the All Ireland co-operative Oncology Research group | |||||||||||||
Full Title: Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer. | |||||||||||||
Medical condition: Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive. | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002066-32 | Sponsor Protocol Number: BEB-13 | Start Date*: 2017-11-10 | |||||||||||
Sponsor Name:Amryt Research Limited | |||||||||||||
Full Title: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa | |||||||||||||
Medical condition: Inherited Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) DE (Completed) ES (Ongoing) GR (Completed) HU (Completed) CZ (Completed) BE (Completed) DK (Completed) IT (Ongoing) HR (Completed) FR (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001510-15 | Sponsor Protocol Number: CNTO1959UCO2002 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and G... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005068-13 | Sponsor Protocol Number: I4T-MC-JVDE | Start Date*: 2015-08-07 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma a... | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) PL (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001179-36 | Sponsor Protocol Number: RHB-104-01 | Start Date*: 2015-07-24 | |||||||||||
Sponsor Name:RedHill Biopharma Ltd. | |||||||||||||
Full Title: A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severe... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014912-36 | Sponsor Protocol Number: SIM001 | Start Date*: 2009-09-22 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Behandling vid Langerhans cellhistiocytos (LCH) | ||
Medical condition: Langerhans cell histiocytosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-005637-38 | Sponsor Protocol Number: TREnd_trial | Start Date*: 2012-09-07 | |||||||||||
Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS | |||||||||||||
Full Title: PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN... | |||||||||||||
Medical condition: ADVANCED BREAST CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002140-27 | Sponsor Protocol Number: 112909 | Start Date*: 2012-04-12 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pne... | ||||||||||||||||||
Medical condition: Healthy volunteers (Vaccination against Streptococcus pneumoniae in healthy children previously enrolled in study 10PN-PD-DIT-037 (111188).) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003984-20 | Sponsor Protocol Number: LSK-AM301 | Start Date*: 2017-12-11 |
Sponsor Name:Elevar Therapeutics, Inc | ||
Full Title: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care ... | ||
Medical condition: Advanced or Metastatic Gastric Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000445-19 | Sponsor Protocol Number: SAKK 17/04 | Start Date*: 2007-07-27 | |||||||||||
Sponsor Name:Swiss group for clinical cancer research | |||||||||||||
Full Title: Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial | |||||||||||||
Medical condition: Patients with pleural mesothelioma, T<=3, N<=2, M0 (IMIG-system) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003798-82 | Sponsor Protocol Number: R1578 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease; The STOP-ACEi Trial | |||||||||||||
Medical condition: Progressive, advanced (stage 4 or 5) chronic kidney disease (CKD). NB. There was not an appropriate therapeutic area in the drop down menu in E1-1. Have selected 'Male diseases of the urinary and... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
